Sino Biopharmaceutical Limited Profit Margin

Sino Biopharmaceutical Limited (SBMFF) currently reports a profit margin of 7.09% as of June 2026. That compares with 12.67% in the prior-year period — down 44.0% year over year. That is below the Healthcare sector average of 9.71%. Use the charts on this page to explore Sino Biopharmaceutical Limited's profit margin history and peer comparisons.

Sino Biopharmaceutical Limited's profit margin decreased from 12.67% to 7.09% — a 44.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sino Biopharmaceutical Limited's profit margin of 7.09% is lower than the Healthcare sector average of 9.71%. That is roughly 27.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sino Biopharmaceutical Limited's current 7.09% should be judged against Healthcare norms (sector average: 9.71%) and against SBMFF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 7.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.71%. From there, open related valuation or income-statement pages for Sino Biopharmaceutical Limited, and consider following SBMFF for alerts when major investors trade the stock.